Quantcast
Home > Quotes > KOD

Kodiak Sciences Inc Common Stock (KOD) Quote & Summary Data

KOD 
$10
*  
0.70
7.53%
Get KOD Alerts
*Delayed - data as of Dec. 7, 2018  -  Find a broker to begin trading KOD now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 10.50 / $ 8.2201
Share Volume
142,863
50 Day Avg. Daily Volume
N/A
Previous Close
$ 9.30
52 Week High / Low
$ 11.10 / $ 7.2501
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
142,863
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $10 is 37.93% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 10.50 $ 11.10
 Low: $ 8.2201 $ 7.2501

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our most advanced product candidate is KSI-301, a biologic therapy built with our antibody biopolymer conjugate platform, or ABC Platform, which is designed to maintain potent and effective drug levels in ocular tissues. We believe that KSI-301, if approved, has the potential to become an important anti-VEGF therapy in wet age-related macular degeneration, or wet AMD, and diabetic retinopathy, or DR. KSI-301 and our ABC Platform were developed at Kodiak, and we own worldwide rights to those assets, including composition of matter patent protection for KSI-301. We have applied our ABC Platform to develop additional product candidates beyond KSI-301, including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate. We intend to progress these and other product candidates to address high-prevalence ophthalmic diseases.  ... More ...  


Risk Grade

Where does KOD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 9.33
Open Date:
Dec. 7, 2018
Close Price:
$ 10
Close Date:
Dec. 7, 2018

Consensus Recommendation

Analyst Info